<DOC>
	<DOCNO>NCT00199238</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety rupatadine treatment CIU symptoms.To assess clinical efficacy dose range rupatadine fumarate ( 5mg , 10mg , 20 mg ) compare placebo relief CIU symptom .</brief_summary>
	<brief_title>Efficacy Rupatadine 5 , 10 20 Mg Chronic Idiopathic Urticaria</brief_title>
	<detailed_description>Objectives : To evaluate efficacy safety rupatadine treatment CIU symptoms.To assess clinical efficacy dose range rupatadine fumarate ( 5mg , 10mg , 20 mg ) compare placebo relief CIU symptom . Methodology : A dose-finding multicentre , double-blind , randomise , placebo-controlled , parallel–group study Number patient ( plan analyse ) : 248 patient . 62 patient allocated treatment group . 283 patient randomise analyse . Diagnosis criteria inclusion : Man woman age 12 65 . Documented history active CIU ( urticaria wheal ) without associate angioedema least three day per week last 6 week prior Day 0 . Active CIU ( score ³2 label moderate pruritus ) least 3 day ( necessarily consecutive day ) week inclusion total score active CIU ³6 label moderate pruritus 3 day . Results standard laboratory biochemistry haematology test obtain screen within acceptable limit assess investigator . Patient sign informed consent form . Test product , dose , mode administration , batch N° : Rupatadine 5,10 20 mg tablet ; oral dose 1 tablet/day 4 consecutive week ; batch 0102 ( France ) batch 0203 ( Hungary , Romania Argentina ) . Expiry date : 12/2003 ( France ) 10/2004 ( Hungary , Romania Argentina ) . Duration treatment : Oral administration test formulation ( 5 , 10 , 20 mg ) placebo daily , 4 consecutive week . Reference therapy : Placebo tablet , 1 tablet/day 4 consecutive week . Criteria evaluation ( efficacy ) : Primary efficacy measure treatment compare frequency severity symptom CIU measure patient term change mean pruritus score ( MPS ) 4-week treatment period.Secondary efficacy measure include change baseline 4-week treatment period mean number wheal ( MNW ) score ; mean total symptom score ( MTSS ) , calculate sum MPS ( Mean pruritus symptom ) MNW ( Mean number wheal ) score interference sleep daily activity due urticaria symptom Criteria evaluation ( safety ) : AEs , laboratory test vital sign</detailed_description>
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Cyproheptadine</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<mesh_term>Histamine Antagonists</mesh_term>
	<criteria>1 . Man woman age 12 65 2 . Documented history active CIU ( urticaria wheal ) without associate angioedema least three day per week last 6 week prior Day 0 3 . Active CIU ( score ³2 label moderate pruritus ) least 3 day ( necessarily consecutive day ) week inclusion total score active CIU ³6 label moderate pruritus 3 day 4 . Results standard laboratory biochemistry haematology test obtain screen within acceptable limit assess investigator 5 . Patient sign informed consent form 1 . CIU associate underlying disease ( Hodgkin ’ disease/vasculitis/lupus erythematous/hepatitis ) 2 . Patient systemic topical medication CIU and/or inferior washout period state follow : H1receptor antagonist : fexofenadine ( 10 day prior Day 0 ) , loratadine , cetirizine , hydroxyzine , diphenhydramine , cyproheptadine , etc . ( 3 day prior Day 0 ) H2receptor antagonist : cimetidine , ranitidine famotidine ( 2 day prior Day 0 ) H1 H2receptor antagonist : doxepin ( 7 day prior Day 0 ) Leukotriene antagonist : zafirlukast montelukast ( 4 day prior Day 0 ) Corticosteroids : prednisone methylprednisolone ( 7 day prior Day 0 ) Tricyclic antidepressant : imipramin amitriptilin ( 30 day prior Day 0 ) The informed consent form must sign prior washout period set . 3 . Physical urticaria due cold , heat , and/or sun 4 . Cholinergic urticaria 5 . Patient take potential inhibitor CYP3A4 isozyme cytochrome P450 ketoconazole , erythromycin and/or tricyclic antidepressant , e.g . imipramin , amitriptilin , etc . 6 . Urticaria due know aetiology ( e.g. , medication , insect bite , food , etc ) 7 . Patient unresponsive antihistaminic treatment 8 . Patient psychiatric disorder , vascular , hepatic , neurological , endocrine major systemic disease 9 . Pregnant lactate female 10 . Patient heart abnormality clinical relevance pathological change heart rate 11 . Patient medication could interfere drug effect interpretation efficacy parameter 12 . Subject handle dangerous machinery drive integral part his/her occupation 13 . Patient hereditary angioedema isolate dermographism 14 . Patient disease cause parasite</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>ANTIHISTAMINE</keyword>
	<keyword>RUPATADINE</keyword>
	<keyword>WHEAL</keyword>
	<keyword>FLARE</keyword>
	<keyword>DERMATOLOGY</keyword>
</DOC>